Analysts hailed Cunningham’s experience as a boost to GeneDx as the company tries to enter new markets and maintain its leadership in a competitive sector.
GeneDx said Wednesday it has appointed Everett Cunningham as CEO effective on or before Dec. 15.
Cunningham is joining the genetic testing company to replace Katherine Stueland, who will step down as CEO and a member of the board when the new leader arrives.
Stueland will stay at the company in an advisory role until Jan. 31 to smooth the transition. GeneDx’s sales have nearly tripled since Stueland became CEO in 2021, TD Cowen analysts said in a note to investors.
However, GeneDx’s performance has “been more uneven” in recent quarters as “price realization slowed and the market shifted more quickly to lower-margin whole genomes,” the analysts said. Those issues mean “the management transition likely won’t be a total surprise to the market.”
Cunningham is joining from Quanterix and earlier in his career held leadership roles at Illumina, Exact Sciences, GE HealthCare and Quest Diagnostics. The incoming CEO’s experience could prove valuable as GeneDx seeks to optimize revenue cycle management, enter new markets and maintain its leadership in a competitive sector, the analysts said.
The analysts named Cunningham’s experience at Exact Sciences as particularly relevant to GeneDx. The primary care provider channel is core to Exact Sciences. The channel represents nearly two-thirds of the rare and undiagnosed genetic disease opportunity open to GeneDx, but it is a new call point that likely has very different attributes from the company’s core specialist channel, the analysts said.
Source link







